NVCT Insider Trading Activity and SEC Form 4 Filings
NVCT insider trading summary
Over the past 12 months, insiders at Nuvectis Pharma, Inc. (NVCT) reported 2 open-market purchases worth $1.2M by 2 insiders and no sales on SEC Form 4. Net insider buying was $1.2M.
Latest NVCT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 30, 2026 | Ron Bentsur | Chairman & CEO | Buy | $250K (12,500 @ $20.00) |
| Jun 30, 2026 | Marlio Charles Mosseri | 10% Owner | Buy | $916K (50,000 @ $18.32) |
| Nov 5, 2025 | Matthew L. Kaplan | Director | Buy | $64K (11,000 @ $5.84) |
| Nov 5, 2025 | Juan Sanchez | Director | Buy | $75K (13,000 @ $5.79) |
| Nov 5, 2025 | Ron Bentsur | Chairman & CEO | Buy | $29K (5,000 @ $5.72) |
| Oct 27, 2025 | Marlio Charles Mosseri | 10% Owner | Buy | $457K (72,836 @ $6.28) |
| Oct 24, 2025 | Marlio Charles Mosseri | 10% Owner | Buy | $215K (35,034 @ $6.15) |
| Oct 23, 2025 | Marlio Charles Mosseri | 10% Owner | Buy | $284K (46,900 @ $6.06) |
| Jun 20, 2025 | Marlio Charles Mosseri | 10% Owner | Buy | $45K (5,603 @ $7.99) |
| Jun 18, 2025 | Marlio Charles Mosseri | 10% Owner | Buy | $226K (28,043 @ $8.05) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.